Statins are less effective in common daily practice among patients with hypercholesterolemia: The REALITY-PHARMO study

Current Medical Research and Opinion

Volumn 20, Issue 7, 2004, Pages 1025-1033

  Goettsch, Wim G ^a   Yin, Donald D ^b   Alemao, Evo ^b   Klungel, Olaf H ^c   Stalenhoef, Anton F ^d   Herings, Ron M C ^a,c  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cholesterol, total levels; Daily practice; Goal attainment; Hypercholesterolemia; Potency; Statins

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MEDICAL PRACTICE; MEDICAL RECORD; POPULATION RESEARCH; PRACTICE GUIDELINE; RETROSPECTIVE STUDY;

ADULT; AGED; CHOLESTEROL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NETHERLANDS; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 3242697203     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004114     Document Type: Conference Paper

References (41)

1. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
2. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57
3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
7. CBO. Behandeling en preventie van coronaire hartziekten door verlaging van de plasmacholesterolconcentratie. Utrecht: Dutch Institute for Healthcare Improvement CBO; 1998. Report No.: ISBN 90-6910-211-0 CIP
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
9. Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, Kromhout D, Lindemans AD, Avorn J, et al. Undertreatment of hypercholesterolaemia: a population-based study. Br J Clin Pharmacol 2003;55:389-97
10. Reid FD, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002;88:15-9
11. Hippesley-Cox J, Cater R, Pringle M, Coupland C. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 2003;326:689-73
12. Lalouschek W, Lang W, Greisenegger S, Mullner M. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke 2003;34:105-10
13. Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Clin Ther 2003;25:119-38
14. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001;8:383-90
15. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64
16. Weber W. Drug firm withdraws statin from the market. Lancet 2001;358
17. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62
18. Herings RM, Leufkens HG, Heerdink ER, Klungel OH, Breekveldt-Postma NP. Chronic Farmacotherapy Forever. Utrecht, The Netherlands: PHARMO Institute; 2002. Report No:ISBN 90-806967-2-2
19. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417-426
20. Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001;19:655-65
21. Herings RM, Leufkens HG, Vandenbroucke JP. Acute myocardial infarction and prior antibiotic use. JAMA 2000;284:2998-9
22. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999;354:127-8
23. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13
24. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16:366-85; discussion 365
25. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999;19:187-95
26. Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001;322:11-5
27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
28. Erkens JA, Klungel OH, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. Diabetes Care 2001;24:1428-32
29. Erkens JA, Klungel OH, Herings RM, Stolk RP, Spoelstra JA, Grobbee DE, et al. Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients. Eur Heart J 2002;23:1575-9
30. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
31. Twisk J, de Vente W. Attrition in longitudinal studies. How to deal with missing data. J Clin Epidemiol 2002;55:329-37
32. Stokes M, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. Cary, NC, USA: SAS Institute; 1995. Report No.: SAS Publications order # 55320
33. Health-Council-of-the-Netherlands. Cholesterol. Den Haag: Health Council of the Netherlands; 1990. Publication no. 1990/5
34. Bandyopadhyay S, Bayer AJ, O'Mahony MS. Age and gender bias in statin trials. QJM 2001;94:127-32
35. LaRosa JC. Understanding risk in hypercholesterolemia. Clin Cardiol 2003;26:13-6
36. Thomas S, Weijden Tvd, Drenth BBv, Haverkort AFM, Hooi JD, Laan JRvd. NHG-Standaard Cholesterol. Huisarts Wet 1999;42:406-17
37. van Loenen, AC. Farmaceutisch Kompas: medisch farmaceutische voorlichting/uitgave van de Comissie Farmaceutische Hulp van het College voor zorgverzekeringen. Amstelveen, Vol. 537, 2004
38. Clearfield MB. Statins: balancing benefits, efficacy and safety. Expert Opin Pharmacother 2002;3:469-77
39. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, Maryland, USA: National Institutes of Health. National Heart, Lung, and Blood Institute; 2001 May 2001. NIH Publication No:01-3670
40. Luijn JCF. Herziening voorwaarden aanspraak cholesterol-verlagende middelen. Amstelveen: Dutch College for Health Insurance (CVZ); 2002. Report No.: 114
41. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of 'statin' lipid-lowering drugs compared with guidelines. Arch Intern Med 2001;161:53-8